GlassScriptPhysician profile
Naveed S Vehra
NPI 1609889948
$15,293.45
in general payments reported to CMS, 2019-2025
58 companies · $2,869 in 2025
The $2,869 reported for 2025 was more than what 78% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,802 · 2020: $1,105 · 2021: $1,991 · 2022: $2,231 · 2023: $1,666 · 2024: $2,629 · 2025: $2,869.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,164.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,782.88 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Ucb, INC. | $1,344.31 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Alexion Pharmaceuticals, INC. | $1,315.90 | 2019-2025 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $1,199.23 | 2019-2025 | |
| Biogen, INC. | $924.07 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Teva Pharmaceuticals USA, INC. | $890.92 | 2019-2025 | Austedo Xr, Ajovy, Austedo |
| Medtronic USA, INC. | $851.63 | 2019-2020 | |
| Emd Serono, INC. | $715.78 | 2019-2024 | Mavenclad |
| Argenx US, INC. | $514.00 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $447.16 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Allergan, INC. | $421.44 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $397.95 | 2019-2025 | Nuplazid |
| Pfizer INC. | $385.68 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $344.41 | 2019-2025 | Rytary, Crexont |
| Genentech USA, INC. | $344.27 | 2019-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Naveed Vehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.